Skip to main content

Table 3 Laboratory data before and after the treatment of thalidomide

From: Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study

Inflammatory markers (median [interquartile range])

3 months before

Baseline

3 months

6 months

9 months

12 months

CRP (mg/L)

9.0 (5.0, 15.0)

16.50 (3.75, 27.75)

5.50 (3.25, 21.23)

5.0 (1.0, 13.0)

6.0 (2.50,28.0)

1.0 (1.0,14.50)

ESR (mm/h)

14.0 (8.0, 30.0)

24.0 (8.0, 36.0)

9.50 (5.75, 16.0)

8.0 (4.0, 19.0)

8.0 (5.0,19.0)

7.0 (2.75,15.8)

  1. CRP and ESR values were recorded at baseline, 3 months before thalidomide and at 3, 6, 9, and 12 months on thalidomide. Data are median (interquartile range)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096